Expression of the ELAV-like protein HuR in the cytoplasm is associated with endometrial carcinoma progression

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11939-11947

  Wang, Dandan ^a   Wang, Min ^a   Hu, Change ^a   Shuang, Ting ^a   Zhou, Yingying ^a   Yan, Xiaoyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; ER ; Human antigen R; Ishikawa cell; shRNA

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HUR PROTEIN; LIPOCORTIN 5; SHORT HAIRPIN RNA; HU ANTIGEN; SMALL INTERFERING RNA;

ADVANCED CANCER; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; CANCER GRADING; DISEASE COURSE; ENDOMETRIUM TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CYTOPLASM; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA, SMALL INTERFERING;

EID: 84925286231     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2485-9     Document Type: Article

References (32)

1. Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, et al. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. J Gynecol Oncol. 2012;23:251–6.
2. Le J. Obstetrics and Gynecology, 6th ed. Beijing. Beijing: People’s Medical Publishing House; 2005.
3. Weiderpass E, Persson I, Melhus H, Wedrén S, Kindmark A, Baron JA. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 2000;21:623–7.
4. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA. 2010;1:214–29.
5. Kim MY, Hur J, Jeong S. Emerging roles of RNA and RNA binding protein network in cancer cells. BMB Rep. 2009;42:125–30.
6. Hasegawa H, Kakuguchi W, Kuroshima T, Kitamura T, Tanaka S, Kitagawa Y, et al. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br J Cancer. 2009;100:1943–8.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
8. Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, et al. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: Association with cyclooxygenase-2 and prognosis. Cancer. 2008;113:2761–9.
9. Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 2003;63:7591–4.
10. Lim SJ, Lee SH, Joo SH, Song JY, Choi SI. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Res Treat. 2009;41:87–92.
11. Lopez de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol. 2005;2:11–3.
12. Gantt KR, Cherry J, Richardson M, Karschner V, Atasoy U, Pekala PH. The regulation of glucose transporter (GLUT1) expression by the RNA binding protein HuR. J Cell Biochem. 2006;99:565–74.
13. Pryzbylkowski P, Obajimi O, Keen JC. Trichostatin A and 5 Aza-2’ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat. 2008;111:15–25.
14. Denkert C, Weichert W, Winzer KJ, Muller BM, Noske A, Niesporek S, et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res. 2004;10:5580–6.
15. Suswam EA, Nabors LB, Huang Y, Yang X. King PH.IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3’ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005;113:911–9.
16. Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006;66:7948–56.
17. Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, et al. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res. 2008;68:9469–78.
18. Wang J, Wang B, Bi J, Zhang C. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol. 2011;28:S577–85.
19. Ma WJ, Furneaux H. Localization of the human HuR gene to chromosome 19p13.2. Hum Genet. 1997;99:32–3.
20. Wang J, Zhao W, Guo Y, Zhang B, Xie Q, Xiang D, et al. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology. 2009;76:420–9.
21. Gallouzi IE, Steitz JA. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science. 2001;294:1895–901.
22. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J. 2000;19:2340–50.
23. Sheflin LG, Zou A, Spaulding SW. Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun. 2004;322:644–51.
24. Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T, et al. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol. 2009;29:1152–62.
25. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol. 2000;20:760–9.
26. Ishimaru D, Ramalingam S, Sengupta TK, Bandyopadhyay S, Dellis S, Tholanikunnel BG, et al. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol Cancer Res. 2009;7:1354–66.
27. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23:1743–8.
28. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012;14:659–65.
29. Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009;6:575–83.
30. Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, et al. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle. 2010;9:1354–9.
31. Xu F, Zhang X, Lei Y, Liu X, Liu Z, Tong T, et al. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J Cell Biochem. 2010;111:727–34.
32. Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, et al. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther. 2008;7:1496–506.